Un rapport de Global Health 50/50 classe Unitaid parmi les leaders en matière d’équité entre les sexes

Unitaid est fière d’annoncer son impressionnante performance dans le 6e rapport annuel de Global Health 50/50, intitulé « Lieux de travail : pire pour les femmes ». Depuis 2020, Unitaid a été reconnue comme « très performante », obtenant un score très élevé sur l’indice de genre et de santé de Global Health 50/50. Cette reconnaissance démontre notre engagement persistant envers l’égalité des sexes et la diversité dans notre façon de travailler.

L’équité est ancrée dans nos valeurs et nos principes, guidant chaque aspect de notre travail. Nous accordons la priorité à la réduction des inégalités dans l’accès aux produits et services de santé de qualité pour atteindre les objectifs de développement durable. Nos investissements ciblent des outils, des services et des modèles de soins qui améliorent les résultats en matière de santé et répondent aux priorités mondiales en matière de santé, en mettant fortement l’accent sur les problèmes d’accès liés au genre, en particulier pour les femmes et les filles.

« La lutte contre les inégalités est au cœur de notre mission », a déclaré le Dr Philippe Duneton, directeur exécutif d’Unitaid. « Nous accordons la priorité aux investissements et aux produits qui profitent aux populations vulnérables qui font face à des obstacles pour accéder à des soins optimaux. Ces populations varient selon nos domaines d’intervention, mais peuvent inclure les populations clés du VIH, les femmes enceintes, les consommateurs de drogues injectables, les femmes transgenres, les professionnelles du sexe, les hommes homosexuels, les hommes et les enfants présentant des lacunes dans le dépistage et le traitement du VIH, les détenus à risque plus élevé de contracter la tuberculose, les enfants vulnérables susceptibles de contracter des formes graves de tuberculose et les femmes enceintes dans les régions où le paludisme est endémique.

En plus de donner la priorité aux populations vulnérables, nous garantissons un accès abordable aux produits de santé grâce à des modèles d’approvisionnement innovants, à la fabrication nationale, au transfert de technologie et à la mise en place d’un environnement propice à l’accès, y compris la propriété intellectuelle et la réglementation.

Unitaid reconnaît l’importance de la collaboration et de l’engagement avec les organisations et les partenaires les plus proches de la population qui en a le plus besoin. En favorisant des partenariats inclusifs et axés sur la demande, nous nous assurons que notre financement soutient des solutions spécifiques au contexte. Nous nous attendons à ce que les responsables de la mise en œuvre des subventions respectent des normes comparables, renforçant ainsi l’impact de notre travail collectif.

En impliquant de plus en plus les communautés et la société civile, nous pouvons aider à établir des partenariats inclusifs et à favoriser un environnement inclusif qui valorise des points de vue, des antécédents et des expériences variés, autonomisant ainsi les individus et les communautés.

Nous remercions Global Health 50/50 pour leurs recherches approfondies, qui nous inspirent à continuer à travailler pour rendre la santé mondiale plus juste et plus inclusive. Unitaid reste fidèle à son engagement en faveur de l’équité, de l’égalité des sexes et de la promotion de l’accès aux innovations en matière de santé pour tous.

Pour en savoir plus :

Contact pour les médias :

Pour plus d’information ou pour des demandes des médias, veuillez contacter :

Hervé Verhoosel

Chef d’equipe, communication

M : +33 6 22 59 73 54

verhooselh@unitaid.who.int

L’introduction de 30 innovations essentielles permettra à Unitaid de faire un pas décisif vers les objectifs de santé mondiaux d’ici 2030

Le partenariat entre Unitaid et l’OMS a permis de réaliser plus de 60 mises à jour des politiques de santé mondiale, menant à une mise à l’échelle sans précédent de solutions de santé révolutionnaires

Genève – Un partenariat de longue date entre Unitaid et l’Organisation mondiale de la Santé (OMS) accélère la production de preuves visant à informer et rapidement mettre à jour les orientations et lignes directrices en matière de santé mondiale. Ce partenariat a contribué à accélérer l’accès à des interventions vitales qui incluent les meilleurs médicaments contre le VIH et la tuberculose, des outils de pointe pour lutter contre le paludisme et des avancées majeures dans la prévention et les soins du cancer du col de l’utérus et de l’hépatite C pour les personnes vivant dans des contextes à ressources limitées.

Publié alors que les dirigeants mondiaux de la santé se réunissent à Genève pour la 76e Assemblée mondiale de la Santé, le rapport décrit l’impact de cette collaboration relativement aux progrès vers l’atteinte des objectifs en matière de santé de 2030 définis dans les Objectifs de développement durable.

Les programmes de santé du monde entier comptent sur l’OMS pour examiner les données et publier des orientations, leur permettant de déployer de nouveaux produits et interventions de santé de manière sûre et efficace. Les deux agences ont développé une approche collaborative pour condenser le temps nécessaire pour s’assurer que les nouveaux outils parviennent aux pays le plus rapidement possible.

Ce processus garantit que les preuves générées par le travail d’Unitaid peuvent être rapidement traduites en lignes directrices et recommandations émises par l’OMS. Unitaid identifie des solutions de santé prometteuses et travaille avec l’OMS pour façonner et éclairer les idées d’investissement. Unitaid réunit ensuite des partenaires qualifiés pour fournir une recherche de haute qualité et supprimer les obstacles à l’accès afin de permettre une adoption à grande échelle. Sur la base des preuves générées par cette recherche et celle de ses partenaires, l’OMS publie des mises à jour des politiques mondiales et aide les pays à intensifier les produits et interventions vitaux.

Depuis 2017, l’OMS a facilité la conception et la réalisation de plus de 160 études financées par Unitaid. Cette recherche critique a sous-tendu plus de 60 mises à jour des directives sanitaires et des outils de mise en œuvre. Les programmes de santé nationaux et les partenaires mondiaux de mise à l’échelle mettent ensuite en œuvre des interventions vitales qui sont essentielles pour faire progresser les soins aux personnes touchées ou à risque de contracter le VIH, la tuberculose, le paludisme, le cancer du col de l’utérus, l’hépatite C et la COVID-19.

« Depuis sa création, Unitaid aide les pays à accéder à des innovations qui sauvent des vies », a déclaré le Dr Tedros Adhanom Ghebreyesus, directeur général de l’OMS. « L’OMS est fière de travailler avec Unitaid pour identifier les lacunes et concevoir les interventions nécessaires pour protéger et promouvoir la santé. En veillant à ce que les innovations ne restent pas bloquées sur leur chemin vers la mise à l’échelle, l’ensemble du système de santé mondial bénéficie du modèle d’Unitaid.

« L’OMS joue un rôle essentiel dans l’élaboration et l’information des idées d’investissement d’Unitaid. Cela garantit que les preuves générées par nos investissements se traduisent rapidement en orientations mondiales, conduisant à des politiques nationales qui répondent aux besoins des populations les plus mal desservies », a déclaré le Dr Philippe Duneton, directeur exécutif d’Unitaid.

Accédez au rapport, Better Health Solutions, ici.

Contact pour les médias :

Pour plus d’information ou pour des demandes des médias, veuillez contacter :

Hervé Verhoosel

Chef d’equipe, communication

M : +33 6 22 59 73 54

verhooselh@unitaid.who.int

Better health solutions

Unitaid’s investment case 2023-2027

Unitaid salue l’engagement renouvelé du Brésil et du Portugal en faveur de la santé et du bien-être

As leaders from the two nations convened at the Brazil-Portugal Summit this week, a memorandum of understanding was signed reiterating the countries’ shared commitments to universal and equitable access to health, and highlighted Unitaid as a key actor in global health.

The agreement outlines a common vision of the future in which health issues will play an increasingly central role in the well-being of the populations of their countries and in the strengthening of their national economies. They pledged to coordinate efforts so that the treatment of health issues is a factor in reinforcing relations between the two governments at the bilateral, bi-regional and international levels and renewed their commitment to health cooperation within the community of Portuguese-speaking countries (CPLP) for the benefit of all its members.

Notably, the so-called “Carta de Lisboa” emphasizes the centrality of the World Health Organization in dealing with multilateral health issues and the importance of enhancing the performance of organs of the global health architecture, such as Unitaid.

“Unitaid commends the leadership of Brazil and Portugal in advancing collaborative and equitable approaches to health,” said Mauricio Cysne, Senior Advisor, Unitaid. “Strong partnerships such as this one are critical to enabling Unitaid to accelerate global health responses and ensure vital tests, medicines, and other health technologies reach people everywhere they are needed.”

Brazil was one of five founding members of Unitaid in 2006 and has been a strong ally ever since. Portugal’s commitment to Unitaid began during the COVID-19 pandemic and this support has carried over in support of the 2023-2027 Strategy.

Media contact:

For more information and media requests:

Hervé Verhoosel

Team Lead, Communications

M: +33 6 22 59 73 54

verhooselh@unitaid.who.int

Key stakeholders convene ahead of the G20 second health working group to strengthen global collaboration in research and accelerate regional manufacturing for diagnostics

  • G20 co-branded event was conducted by the Department of Pharmaceuticals, GoI, FIND, and Unitaid to discuss efforts for the sustainable development and manufacturing of effective, quality, and affordable diagnostic countermeasures
  • The objectives of the meeting inform the Health Working Group of the G20 Presidency, hosted by India
  • The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of an R&D and manufacturing network for diagnostics

GOA, INDIA – 16 April 2023. The Department of Pharmaceuticals, Government of India, FIND, and Unitaid co-hosted a high-level meeting to strengthen cooperation and enable sustainable development and manufacturing of effective, quality, and affordable diagnostic countermeasures prior to the G20 second health working group meeting, which will take place on 17–19 April 2023 in Goa, India. Stakeholders in attendance included representatives of the Government of India, G20 Member States (Australia, France, United Kingdom, Indonesia, Russia, Brazil, and observers Mauritius, Netherlands, and Oman), international organizations, and over 20 diagnostics manufacturers from around the world.

While inaugurating the event, S Aparna, Secretary of the Department of Pharmaceuticals, said: “The centrality of diagnostics extends far beyond testing for a pandemic. Diagnostics are key to preventing and treating diseases optimally and, by extension, achieving universal health coverage (UHC). The Government of India is committed to ensuring quality, affordability, and access to diagnostics. We hope that the deliberations from today will be taken forward at the second Health Working Group meeting tomorrow.”

Regional development of diagnostics products through region-appropriate research and decentralized production of diagnostics can help reduce disparities, enhance health security, including pandemic prevention, preparedness, and response capabilities, support UHC, and contribute to regional economic growth.

Sanjay Sarin, Vice President of Access at FIND, said: “The pandemic has bolstered the role of a more decentralized model for manufacturing diagnostics, one that combines global and regional manufacturing alike, in support of equitable and sustainable access to diagnostics worldwide. In line with the priorities of the G20, we believe that decentralized manufacturing supports the broader mission of expanding access to diagnostics and achieving UHC.”

The meeting built on a successful 2-day technical workshop on 13–14 April in Goa, India, organized by FIND and Unitaid and attended by over 20 diagnostics manufacturers from 13 countries. The workshop focused on the development, manufacturing, and commercialization of tests for low- and middle-income countries (LMICs), and the need to accelerate regional production of diagnostics in LMICs. It provided an opportunity for diagnostic manufacturers to deliberate on the enabling factors required for the sustainability of decentralized diagnostic R&D and manufacturing.

As a result of the workshop, manufacturers clearly stated their interest in establishing partnerships to facilitate the transfer of technology, know-how, and capacity building.  Manufacturers also highlighted the need for countries to develop national diagnostic strategies with concrete budget allocations and procurement frameworks prioritizing sourcing of regionally manufactured tests. They stressed the need for governments and development partners to continue strengthening regulatory mechanisms and to make clear commitments to facilitate harmonization and fast-track regulatory processes for regionally manufactured products.

Finally, in line with the India G20 Presidency goals, there was agreement that funding needs to be made available to create and maintain capacity for coordinated global manufacturing, R&D and technology transfer.

Robert Matiru, Director of Programmes of Unitaid, said: ” The problems are clear. It is now critical that we take bold action and prioritize innovations that drive the availability and equitable access to essential health technologies, including diagnostics. At Unitaid, we are committed to adopting a market-based approach to accelerate, expand and sustain regional production, and will work with our partners to explore all solutions towards building more resilient health access globally.

The meeting today provided an opportunity for diagnostics industry partners to put forward their recommendations to G20 Member States so that they can be taken into consideration during the G20 second health working group meeting which has outlined “strengthening cooperation in the pharmaceutical sector with a focus on availability & access to safe, effective, quality, and affordable medical countermeasures — diagnostics, vaccines, and therapeutics” as a key priority.

Summarizing the discussions, Dr. Rajiv Bahl, Secretary of the Department of Health Research and Director-General of the Indian Council of Medical Research said: “The need for diagnostics is immense. As we move forward into the second health working group meeting, it will be important for G20 countries to consider measures for greater investment in diagnostics, collaborative R&D, and manufacturing networks that complement existing efforts and strengthen local capacities, and address policy, infrastructure, and human resource related challenges.”

About the Department of Pharmaceuticals

The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, Government of India focuses on the development of pharmaceutical sector in India and regulates various complex issues related to pricing and availability of medicines at affordable prices, research & development, protection of intellectual property rights and international commitments related to pharmaceutical sector which required integration of work with other Ministries. The Department’s vision is to make India the largest global provider of quality medicines at reasonable price. For more information, please visit https://pharmaceuticals.gov.in/

About FIND

FIND seeks to ensure equitable access to reliable diagnosis around the world. We connect countries and communities, funders, decision-makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. We are working to save 1 million lives through accessible, quality diagnosis, and save US$1 billion in healthcare costs to patients and health systems. We are co-convener of the Access to COVID-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. For more information, please visit www.finddx.org

About Unitaid

Unitaid is a global health organization engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, affordably, and effectively, in low- and middle-income countries. Its work includes developing and funding initiatives to address major diseases such as HIV, malaria, and tuberculosis, as well as advanced HIV disease, cervical cancer, hepatitis C, and cross-cutting areas, such as fever management. Unitaid also recently deployed its expertise and capabilities to develop and deliver therapeutics (including oxygen) and diagnostics for the COVID-19 pandemic, serving as a lead agency of the Access to COVID Tools Accelerator. Unitaid’s new Strategy, 2023-2027 includes developing and investing in interventions to respond to global health emergencies and to transform women’s and children’s health. Unitaid is hosted by the World Health Organization. For more information, please visit www.unitaid.org

Media contacts

For more information and media requests:

 

FIND

Karishma Saran

Senior Manager, Advocacy and Communications

M: +41 79 823 49 18

media@finddx.org

 

Unitaid

Hervé Verhoosel

Head of Communications

M: +41 79 249 35 29

verhooselh@unitaid.who.int

Unitaid et le Fonds pour les technologies innovantes en santé mondiale (GHIT) renforcent leur collaboration pour améliorer l’accès aux outils de santé essentiels

Tokyo and Geneva – The Global Health Innovative Technology Fund (GHIT Fund) and Unitaid have signed a cooperation framework that aims to strengthen collaboration between the two agencies to increase cooperation between the Japanese research and development industry and the broader global health response. The partnership will focus on tackling complex challenges such as emerging drug resistance in tuberculosis (TB) and malaria and shifting patterns of vector-borne diseases due to climate change. 

By reinforcing links between the GHIT Fund’s research and development pipeline and Unitaid’s expertise in product introduction and access, the framework will further efforts to connect partners and ideas dealing with topics of health innovation, access, and scale. 

The agreement unites the two agencies at a broad strategic level and creates a channel for continuous collaboration, scanning the innovation pipeline for late-stage products that address the most pressing global health needs. This work will further efforts to ensure vulnerable and underserved populations have access to better health products and support progress towards universal health coverage. 

“GHIT looks forward to strengthening the strategic partnership with Unitaid as both organizations enter the next chapter of respective 5-year strategic plans. We strive for seamless transition of GHIT’s innovation pipelines to Unitaid’s expertise in new product introduction and access, bridging to equitable and sustainable access and delivery at scale. We will accelerate the R&D pipeline to maximize impact,” said Dr. Osamu Kunii, CEO of the GHIT Fund. 

“The recent COVID-19 pandemic has illustrated the importance of global collaboration in solving global problems,” said Dr Philippe Duneton, Executive Director of Unitaid. “Unitaid’s reinforced partnership with the GHIT Fund will leverage ties with Japanese innovators who are addressing some of today’s most pressing health challenges. This will improve equitable access to the benefits of new medicines, diagnostics and health technologies for people everywhere, in pursuit of a healthier, safer world for all.”  

About Unitaid

Unitaid is a global health agency engaged in finding innovative solutions to prevent, diagnose, and treat diseases more quickly, cheaply, and effectively, in low- and middle-income countries. Its work includes funding initiatives to address major diseases such as HIV, malaria, and tuberculosis, as well as HIV co-infections and co-morbidities including advanced HIV disease, cervical cancer, and hepatitis C, and cross-cutting areas, such as fever management. Unitaid is now applying its expertise to address challenges in advancing new therapies and diagnostics for the COVID-19 pandemic, serving as a key member of the Access to COVID-19 Tools (ACT) Accelerator, co-leading with Wellcome the Therapeutics Pillar and participating in the Diagnostics Pillar. Unitaid is hosted by the World Health Organization.

Media contact:

For more information and media requests:

Maggie Zander

Communications Officer

M: +41 79 593 17 74

zanderm@unitaid.who.int